Overview

A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders

Status:
NOT_YET_RECRUITING
Trial end date:
2025-06-25
Target enrollment:
Participant gender:
Summary
To assess the efficacy and safety of Inebilizumab in Chinese adult patients with neuromyelitis optica spectrum disorders.
Phase:
PHASE4
Details
Lead Sponsor:
Hansoh BioMedical R&D Company
Collaborator:
Horizon Therapeutics Ireland DAC
Treatments:
inebilizumab